News

Press Releases

Astrocyte Pharmaceuticals Raises $6M Series A to Advance Next Generation Stroke and TBI Treatment to the Clinic

Groton, CT, May 3, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries, announced today the completion of the Company’s Series A financing that raised $6.0M. Astrocyte is progressing its lead development candidate AST-004, based upon technology originally licensed from The University […]

Astrocyte Pharmaceuticals Announces Expanded Clinical Advisory Board

Groton, CT, December 1, 2020 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company advancing neuroprotective treatments, announced the establishment of its Clinical Advisory Board (CAB) with leading stroke and traumatic brain injury (TBI) clinical experts.   The Board will be Chaired by current advisor Dr. Jeffrey L. Saver, and include ongoing advisor Dr. David W. […]

Astrocyte Pharmaceuticals Presents NHP Stroke Study at International Stroke Conference

Cambridge, MA, February 21, 2020 – Astrocyte Pharmaceuticals Inc. presented the results of a key preclinical efficacy study today at the International Stroke Conference in Los Angeles demonstrating the efficacy of AST-004 in a non-human primate (NHP) model of stroke.  Dr. Theodore Liston, Vice President of Research at Astrocyte, presented the talk entitled, “Significant Efficacy […]

Jeffrey L. Saver to Chair Astrocyte Pharmaceuticals’ Clinical Advisory Board

Cambridge, MA, December 11, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced that Jeffrey L. Saver, M.D., has joined the company’s Scientific Advisory Board and will chair the company’s Clinical Advisory Board. Astrocyte Pharmaceuticals is developing small molecule therapeutics for the treatment of brain injuries, including patients who have suffered a […]

Astrocyte Pharmaceuticals Awarded $3M NIH Small Business Grant to Advance TBI and Concussion Therapeutic

Cambridge, MA, September 19, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that it has been awarded a $3 million Phase 2 Small Business Innovation Research (SBIR) Grant from the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH).  The grant provides funding to advance […]

Astrocyte Pharmaceuticals Awarded Alzheimer’s Disease Research Grant

Cambridge, MA, September 18, 2018 – Astrocyte Pharmaceuticals, Inc., a privately held pharmaceutical company, announced today that it has been awarded $287k Phase 1 Small Business Technology Transfer (STTR) Grant from the National Institutes of Health’s (NIH) National Institute On Aging (NIA).  The grant provides funding to further evaluate and advance its promising neuroprotectant drug […]

see all

Developing innovative neuroprotection therapies for Traumatic Brain Injuries (TBI), concussions, stroke, and neurodegenerative disorders